Shares of Perrigo Co. PRGO, +2.98% gained 2.1% in trading on Monday after the company said a Food and Drug Administration advisory committee meeting has been scheduled to review the application for an over-the-counter birth control. The meeting is set for Nov. 18. The medication, a daily oral contraceptive, is called Opill. If approved, it would be the first OTC birth control pill in the U.S. Perrigo's stock is up 2.6% this year, while the broader S&P 500 SPX, +0.87% has declined 14.6%.
Continue reading your article with a FrontPage News Subscription
Already a Subscriber? Sign In
VIEW SUBSCRIPTION OPTIONS
Support independent journalism by subscribing